Literature DB >> 32010361

LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW.

A Croitoru1,2, I Dinu1, V Herlea3, G Becheanu3, M Grasu4, I Lupescu4, S O Dima5,6, F Buica1,2, T Dumitrascu5, C Lungulescu7, V M Croitoru1, A Tanase8,2, S M Negru9, I M Gramaticu1.   

Abstract

We report the case of a 55-year-old-male with a large cell metastatic pancreatic neuroendocrine carcinoma treated for 14 months with lanreotide autogel having a stable disease (SD) and not responding to chemotherapy. The somatostatin analogues (SSA) were introduced after an episode of diarrhea and controlled the disease. Progression-free survival (PFS) as determined by Computerized Tomography (CT) scans was obtained for 14 months. After more than a year, the patient's health state deteriorated along with progressive disease. The capecitabine-temozolomide regimen was challenged, but after three cycles, a rapid clinical decline was noted.
CONCLUSION: This unexpected event (diarrhea) in the course of the disease could represent the beginning of carcinoid syndrome. While the lanreotide autogel helped the episode of diarrhea pass, it also helped gain control over the disease itself. ©by Acta Endocrinologica Foundation.

Entities:  

Keywords:  Large cell pancreatic carcinoma; Nueorendocrine tumor; lanreotide autogel

Year:  2019        PMID： 32010361      PMCID： PMC6992400          DOI： 10.4183/aeb.2019.390

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN： 1841-0987            Impact factor:   0.877


  28 in total

1.  ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.

Authors:  R Garcia-Carbonero; H Sorbye; E Baudin; E Raymond; B Wiedenmann; B Niederle; E Sedlackova; C Toumpanakis; M Anlauf; J B Cwikla; M Caplin; D O'Toole; A Perren
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 2.  Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.

Authors:  John Ramage; Boris G Naraev; Thorvardur R Halfdanarson
Journal:  Semin Oncol       Date:  2018-10-24       Impact factor: 4.929

3.  Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.

Authors:  M L Fjällskog; D P Granberg; S L Welin; C Eriksson; K E Oberg; E T Janson; B K Eriksson
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

4.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Authors:  C G Moertel; L K Kvols; M J O'Connell; J Rubin
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

5.  First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan R Strosberg; Robert L Fine; Junsung Choi; Aejaz Nasir; Domenico Coppola; Dung-Tsa Chen; James Helm; Larry Kvols
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

6.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

7.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Authors:  H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

8.  PROGNOSTIC FACTORS IN PATIENTS WITH SURGICAL RESECTION OF PANCREATIC NEUROENDOCRINE TUMOURS.

Authors:  S O Dima; T Dumitrascu; C Pechianu; R T Grigorie; V Brasoveanu; A Sorop; I Lupescu; R Purnichescu-Purtan; A Croitoru; N Bacalbasa; A Tanase; D R Tomescu; V Herlea; I Popescu
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

Review 9.  Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study.

Authors:  Beata Kos-Kudła
Journal:  Contemp Oncol (Pozn)       Date:  2015-12-22

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.